在用典型或非典型抗精神病药物治疗的大鼠大脑中，DARPP - 32和NCS - 1的表达未发生改变。
DARPP-32 and NCS-1 expression is not altered in brains of rats treated with typical or atypical antipsychotics.
作者信息
Souza Bruno R, Motta Bernardo S, Rosa Daniela V F, Torres Karen C L, Castro Adalberto A, Comim Clarissa M, Sampaio André M, Lima Fabrício F, Jeromin Andreas, Quevedo João, Romano-Silva Marco A
机构信息
Laboratório de Neurociências, Departamento de Saúde Mental, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av Alfredo Balena 190, Belo Horizonte, MG 30130-100, Brazil.
出版信息
Neurochem Res. 2008 Mar;33(3):533-8. doi: 10.1007/s11064-007-9470-2. Epub 2007 Aug 31.
Dopamine-mediated neurotransmission imbalances are associated with several psychiatry illnesses, such as schizophrenia. Recently it was demonstrated that two proteins involved in dopamine signaling are altered in prefrontal cortex (PFC) of schizophrenic patients. DARPP-32 is a key downstream effector of intracellular signaling pathway and is downregulated in PFC of schizophrenic subjects. NCS-1 is a neuronal calcium sensor that can inhibit dopamine receptor D2 internalization and is upregulated in PFC of schizophrenic subjects. It is well known that dopamine D2 receptor is the main target of antipsychotic. Therefore, our purpose was to study if chronic treatment with typical or atypical antipsychotics induced alterations in DARPP-32 and NCS-1 expression in five brain regions: prefrontal cortex, hippocampus, striatum, cortex and cerebellum. We did not find any changes in DARPP-32 and NCS-1 protein expression in any brain region investigated.
多巴胺介导的神经传递失衡与多种精神疾病有关，如精神分裂症。最近有研究表明，参与多巴胺信号传导的两种蛋白质在精神分裂症患者的前额叶皮质（PFC）中发生了改变。DARPP - 32是细胞内信号通路的关键下游效应器，在精神分裂症患者的前额叶皮质中表达下调。NCS - 1是一种神经元钙传感器，可抑制多巴胺受体D2的内化，在精神分裂症患者的前额叶皮质中表达上调。众所周知，多巴胺D2受体是抗精神病药物的主要靶点。因此，我们的目的是研究使用典型或非典型抗精神病药物进行长期治疗是否会导致五个脑区（前额叶皮质、海马体、纹状体、皮质和小脑）中DARPP - 32和NCS - 1表达的改变。我们在所研究的任何脑区中均未发现DARPP - 32和NCS - 1蛋白表达有任何变化。
Zotero 插件